一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (376k)
Article in Japanese

Case Report

Development of asthma during nivolumab therapy in a patient with advanced non-small cell lung cancer

Taisuke Isono  Naohiko Ogawa  Mayuko Tani  Masaru Nishitsuji  Koichi Nishi 

Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital

ABSTRACT

Although nivolumab is applied as standard second-line chemotherapy for non-small cell lung cancer, it induces many immune-related adverse events. A 41-year-old man underwent palliative radiation therapy and chemotherapy for a cStage ⅣA (cT4N0M1b, pancreas) squamous cell lung cancer. He was treated with nivolumab as fourth-line therapy and had a partial response after three cycles of nivolumab. After 32 cycles of nivolumab, he had cough and dyspnea at night or in the early morning. Based on elevated fractional exhaled nitric oxide levels and the clinical course, he was diagnosed with asthma. Fluticasone furoate / vilanterol trifenatate and montelukast were administered, and his respiratory symptoms improved. Remaining alert for asthma may be required during immune checkpoint inhibitor anticancer therapy.

KEYWORDS

Nivolumab  Asthma  Lung cancer  Immune checkpoint inhibitor 

Received 31 Jan 2019 / Accepted 11 Mar 2019

AJRS, 8(4): 278-282, 2019

Google Scholar